STTK on Nasdaq

Shattuck Labs, Inc.

We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 (“DR3”) blocking antibodies for the treatment of.2

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Galena Biopharma, Kitov Pharma or 60 DEGREES PHARMACEUTICALS, INC., or pick any stock.

  • TickerSTTK on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersDover, United States2
  • Incorporated inDE3
  • Business address500 W. 5Th Street, Austin, Tx 787013
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900RMK6YBDXP3NW042
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o CAPITOL SERVICES, INC., 108 LAKELAND AVE., 19901 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 60353642

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 (“DR3”) blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Our expertise in protein engineering and the development of novel tumor necrosis factor (“TNF”) receptor therapeutics come together in our lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway than TL1A blocking antibodies.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-5150.8%Operating margin5
-4880.9%Net margin5
-82.5%Revenue growth, 20255
-59.2%Return on equity5
-$40.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$35.3M

Out of $1.0M in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$1.0M in 2025−90% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $9.9M$9.9M20192020: $9.9M$9.9M2020+0%2021: $30.0M$30.0M2021+202%2022: $652.0K$652.0K2022−98%2023: $1.7M$1.7M2023+154%2024: $5.7M$5.7M2024+245%2025: $1.0M$1.0M2025−83%
Operating income6789105-$51.5M in 2025+105% since 2019
-$150.0M-$100.0M-$50.0M02019: -$25.1M-$25.1M20192020: -$36.9M-$36.9M2020+47%2021: -$45.3M-$45.3M2021+23%2022: -$103.3M-$103.3M2022+128%2023: -$92.0M-$92.0M2023−11%2024: -$80.6M-$80.6M2024−12%2025: -$51.5M-$51.5M2025−36%
Net income6789105-$48.8M in 2025+104% since 2019
-$150.0M-$100.0M-$50.0M02019: -$24.0M-$24.0M20192020: -$36.6M-$36.6M2020+53%2021: -$45.0M-$45.0M2021+23%2022: -$101.9M-$101.9M2022+127%2023: -$87.3M-$87.3M2023−14%2024: -$75.4M-$75.4M2024−14%2025: -$48.8M-$48.8M2025−35%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Total revenue$1.0M$5.7M
Research and development$35.3M$67.2M
General and administrative$17.2M$19.1M
Expense from operations$52.5M$86.3M
Loss from operations-$51.5M-$80.6M
Interest income$2.7M$5.2M
Other expense-$4.0K-$17.0K
Total other income$2.7M$5.2M
Net loss-$48.8M-$75.4M
Unrealized gain (loss) on investments$4.0K-$2.0K
Comprehensive loss-$48.8M-$75.4M
Net loss per share basic (in dollars per share)-$0.70-$1.49
Net loss per share diluted (in dollars per share)-$0.70-$1.49
Weighted-average shares outstanding - basic (in shares)69.6M shares50.8M shares
Weighted-average shares outstanding - diluted (in shares)69.6M shares50.8M shares

Compare Shattuck Labs, Inc. with another company

Leadership

Who has led Shattuck Labs, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Taylor Schreiber2020–now

Chair

  1. Josiah Hornblower2020

Chief financial officer

  1. Andrew R. Neill2021–now
2025
Board members and other officers (17)

Timeline

  1. Oct 8, 2020New chief executive Taylor Schreiber becomes CEO13
  2. May 9, 2016Founded Shattuck Labs, Inc. is founded2

Filings

285 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 44 major events, 135 insider forms, 32 large holders, 52 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G/A EDGAR
  2. Aug 11, 20268-K EDGAR
  3. Aug 11, 202610-Q EDGAR
  4. Aug 11, 2026S-8 EDGAR
  5. Jul 17, 2026SCHEDULE 13D/A EDGAR
  6. Jul 7, 20264 EDGAR
  7. Jul 2, 2026144 EDGAR
  8. Jul 2, 20264 EDGAR
  9. Jul 2, 20264 EDGAR
  10. Jul 1, 2026144 EDGAR
  11. Jun 30, 2026144 EDGAR
  12. Jun 17, 2026SCHEDULE 13G EDGAR
  13. Jun 15, 20264 EDGAR
  14. Jun 15, 20264 EDGAR
  15. Jun 15, 2026SCHEDULE 13D/A EDGAR
  16. Jun 11, 20264 EDGAR
  17. Jun 11, 20268-K EDGAR
  18. Jun 11, 2026424B5 EDGAR
  19. Jun 11, 2026SCHEDULE 13D/A EDGAR
  20. Jun 9, 2026424B5 EDGAR

The 285 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

24 open-market trades by officers, directors and large owners since October 2021: 14 buys and 10 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 2, 2026Shukla Abhinav A.Chief Technical OfficerSale410$7.01$2.9KForm 4
Jul 1, 2026Shukla Abhinav A.Chief Technical OfficerSale100$7.07$707Form 4
Jun 30, 2026Shukla Abhinav A.Chief Technical OfficerSale23,365$7.08$165.4KForm 4
Jun 30, 2026Pandite Arundathy N.Chief Medical OfficerSale30,000$7.01$210.3KForm 4
Jun 9, 2026SIEGALL CLAY BDirectorBuy62,500$4.00$250.0KForm 4
May 12, 2026Shukla Abhinav A.Chief Technical OfficerSale2,032$7.01$14.2KForm 4
May 12, 2026Pandite Arundathy N.Chief Medical OfficerSale30,000$6.61$198.3KForm 4
Aug 25, 2025OrbiMed Capital GP IX LLCDirectorBuy6,306,127$0.87$5.5MForm 4
Aug 25, 2025Ashiya MonaDirectorBuy6,306,127$0.87$5.5MForm 4
Dec 4, 2024Green JeremyDirectorBuy133,371$1.25$166.7KForm 4
Dec 4, 2024Green JeremyDirectorSale133,371$1.25$166.7KForm 4
Oct 7, 2024Schreiber TaylorChief Executive OfficerBuy36,500$1.21$44.2KForm 4
Jun 28, 2024Brous TylerDirectorBuy3,000$3.90$11.7KForm 4
Jun 27, 2024Brous TylerDirectorBuy5,416$3.89$21.1KForm 4
Jun 26, 2024Schreiber TaylorChief Executive OfficerBuy14,400$3.47$50.0KForm 4
Mar 6, 2024Stout StephenSee RemarksSale16,004$10.53$168.5KForm 4
Jan 10, 2024Neill Andrew RChief Financial OfficerSale25,000$10.00$250.0KForm 4
Apr 26, 2022Golumbeski GeorgeDirectorBuy28,330$3.63$102.8KForm 4
Apr 22, 2022Golumbeski GeorgeDirectorBuy234$3.67$859Form 4
Apr 21, 2022Golumbeski GeorgeDirectorBuy26,049$3.69$96.1KForm 4

All 24 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 99. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Adage Capital Partners Gp, L.l.c.8,122,179$56.4M0.1%+3,477,222
Redmile Group, LLC6,892,033$47.8M3.2%+1,352,309
Orbimed Advisors LLC6,306,127$43.8M0.8%No change
Prosight Management, LP5,957,877$41.3M7.1%+953,438
BlackRock, Inc.3,935,810$27.3M0.0%+3,425,004
Frazier Life Sciences Management, L.P.3,750,000$26.0M0.6%New
NEXTBio Capital Management LP3,727,348$25.9M11.9%+577,441
Deep Track Capital, LP3,706,734$25.7M0.4%New
Vanguard Capital Management LLC3,207,865$22.3M0.0%+930,689
Pinnacle Associates Ltd1,871,442$13.0M0.1%+503,219
Wellington Management Group Llp1,767,938$12.3M0.0%New
Geode Capital Management, LLC1,584,756$11.0M0.0%+939,051
Clark Estates Inc/ny1,430,167$9.9M2.3%−45,481
Aberdeen Group plc1,405,851$9.8M0.0%+246,530
Point72 Asset Management, L.P.1,170,732$8.1M0.0%+139,683
683 Capital Management, LLC1,157,216$8.0M0.8%+357,216
State Street Corp1,026,394$7.1M0.0%+762,626
Boxer Capital Management, LLC1,000,000$6.9M0.5%New
Vanguard Portfolio Management LLC946,985$6.6M0.0%New
Renaissance Technologies LLC743,761$5.2M0.0%+139,261
Goldman Sachs Group Inc593,324$4.1M0.0%+401,882
TD Asset Management Inc558,876$3.9M0.0%+176,228
Northern Trust Corp520,316$3.6M0.0%+394,255
Vanguard Fiduciary Trust Co463,415$3.2M0.0%+138,827
S&G Foundation435,749$3.0M0.1%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43